The synergistic effect was associated with a modulation of MDR1 (or Pgp) and MRP transporters, both at the gene and protein levels; moreover, activation of the STAT3 cascade and cell migration appeared significantly affected, suggesting that the STAT3/ABC-transporter axis finely regulated efficacy and chemoresistance to sorafenib, thus appearing as a suitable target to overcome the drawbacks of sorafenib-based chemotherapy in hepato-biliary-pancreatic cancers [11]. Here, STAT3 is linked to pancreatic neoplasm.